SCHEMBL4186339

SCHEMBL4186339

Cc1cc(CN(c2ccc3c(c2)cc(C)n3C)S(=O)(=O)c2ccc(Cl)cc2Cl)on1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
KCNH2 Q12809 1/20 0.34
BRPF1 P55201 1/20 0.34
GSTO1 P78417 1/20 0.34
EDNRA P25101 2/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
POLB P06746 2/20 0.33
ALDH1A1 P00352 4/20 0.32
MAPT P10636 3/20 0.32
KDM2B Q8NHM5 1/20 0.32
EDNRB P24530 1/20 0.32
PTGDR Q13258 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
ACLY P53396 2/20 0.32
TRPM8 Q7Z2W7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882690 0.77 BRPF1 (0.45) BRPF1MEN1KMT2AALDH1A1MAPT
SCHEMBL714554 0.65 ALDH1A1 (0.64) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL714553 0.64 ACLY (0.38) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL435737 0.63 RXFP1 (0.47) MEN1KMT2AALDH1A1MAPTACLY
SCHEMBL713590 0.61 KDM4E (0.44) BRPF1PTGDRPTGDR2TRPV4THRB
SCHEMBL8279516 0.58 BRPF1 (0.45) BRPF1MEN1KMT2APOLBALDH1A1
SCHEMBL14018575 0.58 KDM4E (0.48) MEN1KMT2AALDH1A1MAPTPTGDR2
SCHEMBL4878237 0.58 SMN1; SMN2 (0.43) EDNRAKMT2AALDH1A1MAPTEDNRB
SCHEMBL14018589 0.58 SMN1; SMN2 (0.48) KMT2AALDH1A1MAPTTRPV4LMNA
SCHEMBL5794946 0.57 MAPT (0.39) GSTO1MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023735-A1 Sulphonamide Derivatives BIOTIE THERAPIES CORP. (FI) 2009-01-22 US disclosed
EP-1924554-A1 SULPHONAMIDE DERIVATIVES Biotie Therapies Corp. (FI) 2008-05-28 EP disclosed
WO-2007034035-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023735-A1 Sulphonamide Derivatives HCAR1, ADGRE5, ALK DRD2 758/4885DRD3 1548/4885KCNH2 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.